Merger creates Europe’s first broad-based cardiovascular biotech company
International law firm, Bird & Bird, has been advising new client, Trigen, a UK based biotechnology company, on a major transaction with German biotech ProCorde GmbH. The merger of the two companies, which will create Europe’s first broad-based cardiovascular biotech company, involved a complex legal structure raising detailed technical issues of both English and German law.
Representing an important strategic move for both companies, the merged company will be able to make significant progress in research, drug discovery and development for thrombosis and vascular dysfunction, which are the world’s largest cause of premature death and disability.
A team of Bird & Bird lawyers across the firm’s UK and German offices worked on this deal. Corporate partner, Nicola Maguire, led the work in London with the support of partners Erich Michel in Germany and John Wilkinson in London.
Commenting, Dr Sanjay Kakkar, CEO of Trigen Ltd and CEO of the merged company said:
“Bird & Bird’s strong knowledge of the Life Sciences sector and their ability to provide a co-ordinated team from their offices in the UK and Germany were critical to the successful conclusion of this complex transaction.”
Nicola Maguire added:
“The structure of this transaction required our offices in the UK and Germany to work as a team with Trigen to devise solutions which worked under both jurisdictions. Our knowledge of the Life Sciences sector was essential in advising Trigen on the issues raised during the transaction.”
S J Berwin advised ProCorde while the Trigen and ProCorde shareholders were advised by Osborne Clark in the UK and Cameron McKenna in Germany.
For more information, please contact Nicola Maguire on +44 (0) 20 7415 6000 or Larry Cattle on +44 (0) 20 7416 6156.